Main patient’s characteristics
| Parameter | Information |
| Number of patients included | 22 |
| Median age (range) | 66 (54–77) years |
| PSA at baseline | n=20 ≤0.1 µg/L; n=2 >0.1 µg/L |
| EOCG status at baseline | n=22 status 0 |
| Pathological Gleason Score | n= |
| 6 | 3 |
| 7 (3+4) | 10 |
| 7 (4+3) | 6 |
| 8 | 1 |
| 9 (4+5) | 2 |
| pT category | n= |
| pT2N0/Nx, R- | 10 |
| pT2N0/Nx, R+ | 5 |
| pT3a/b N0/Nx, R- | 1 |
| pT3a/b N0/Nx, R+ | 5 |
| pT3a N1, R+ | 1 |
| All vaccinations performed | n=21 (Patient 015 received seven injections in total) |
| Completed immunomonitoring | n=21 (Patient 002 excluded) |
EOCG, Eastern Cooperative Oncology Group; N, nodes; PSA, prostate-specific antigen; R- and R+, negative and positive margins; T, tumor.